Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shire Buys Pfizer's IBD MAdCAM-1 Candidate For Undisclosed Price

Executive Summary

Back on the product trail after its mega merger with Baxalta Inc, Shire PLC has bought global rights to Pfizer Inc.'s investigational biologic PF-00547659 for inflammatory bowel disease.

You may also be interested in...

Biogen reports 10 more Tysabri PML cases including four deaths

Biogen Idec has confirmed that there have been 10 more cases of the rare brain viral infection, progressive multifocal leukoencephalopathy (PML), among multiple sclerosis patients taking Tysabri (natalizumab), a medication that it co-markets with Elan, bringing the total number of confirmed cases to 95 as of 2 February.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts